A multidisciplinary panel used the GRADE approach to develop evidence-based guidance on pharmacologic management of overweight and obesity in US adults, issuing strong recommendations for agents such as semaglutide, tirzepatide, bupropion-naltrexone, and setmelanotide based on moderate-certainty evidence for weight reduction, quality of life, and cardiometabolic outcomes. The guidance highlighted obesity as a chronic disease requiring long-term pharmacotherapy alongside lifestyle interventions, with demonstrated benefits across key complications including type 2 diabetes, cardiovascular disease, heart failure with preserved ejection fraction, metabolic dysfunction–associated steatotic liver disease, obstructive sleep apnea, and osteoarthritis.

Source: Obesity